Advertisement
Advertisement
U.S. Markets close in 1 hr 58 mins
Advertisement
Advertisement
Advertisement
Advertisement

Avalon GloboCare Corp. (AVCO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.4600+0.0150 (+3.37%)
As of 01:34PM EDT. Market open.
Advertisement

Avalon GloboCare Corp.

4400 Route 9 South
Suite 3100
Freehold, NJ 07728
United States
732 780 4400
https://www.avalon-globocare.com

Sector(s)Real Estate
IndustryReal Estate Services
Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Dr. David K. Jin M.D., Ph.D.CEO, Pres & Director360kN/A1968
Ms. Luisa IngargiolaChief Financial Officer350kN/A1968
Ms. Meng LiCOO, Sec. & Director340kN/A1978
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Corporate Governance

Avalon GloboCare Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement